StrainX Bioworks, a synthetic biology startup based in India, has secured $13 million (₹124 crore) in funding as it emerges from stealth mode, marking one of the largest early‑stage investments in the country’s biotech sector. The round was co‑led by Prime Venture Partners and Leo Capital, with participation from Good Startup, Sparrow Capital, Sun Icon Ventures, Dholakia Ventures, and WindT (IIT Delhi) Angels.
Founded by Akshay Mittal and Alok Malaviya, both IIT Delhi alumni, StrainX Bioworks focuses on precision fermentation and synthetic biology to create sustainable alternatives for food, nutrition, materials, and consumer health industries. The company has built an integrated platform covering strain engineering, fermentation, and process scale‑up, enabling large‑scale production of bio‑based materials.
The fresh capital will accelerate StrainX’s expansion into commercial manufacturing, strengthen its R&D capabilities, and support global partnerships. The startup currently employs over 100 scientists and engineers and has completed large‑scale fermentation trials, paving the way for 100,000‑litre operations.
Investors praised StrainX’s scientific depth and execution discipline. Prime Venture Partners highlighted its potential to make India a global hub for biotech innovation, while Leo Capital and Good Startup emphasized the company’s role in advancing sustainable manufacturing.
As StrainX steps out of stealth, it aims to redefine how biology powers industrial production — positioning India at the forefront of the global synthetic biology revolution.
